EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System

The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. 

CLASP: resultados a 2 años del nuevo dispositivo de reparación Mitral

These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions.

The PASCAL system (Edwards) has been authorized for research protocols only in the US.  

At present, patients are being enrolled to the CLASP IID/IIF, set to test the PASCAL against the MitraClip in patients with both functional and degenerative MR. 

If it lives up to its promise, the PASCAL is likely to be authorized by the FDA for use in the clinical arena. 

There are several differences between devices: one is the ability to treat one leaflet after the other, or in tandem. 4th generation MitraClips will offer the same characteristic. 


Read also: Very Short Dual Antiplatelet Therapy after Complex PCI.


The CLASP trial included 124 patients with significant mitral valve regurgitation (≥ 3+) and functional class II to IV who made good candidates for edge-to-edge repair. 

69% of the population had functional mitral valve regurgitation and 60% were in functional class III-IV. Outcomes at 30 days and one year were presented at TCT 2020 and simultaneously published in JACC: Cardiovascular Interventions.

The new outcomes were presented at the EuroPCR; 48 patients that completed the 2 year follow up with 72% survival rate in the functional group and 94% in the degenerative group. 78% of patients presented mitral regurgitation ≤1+, which was accompanied by improved end diastolic volume and functional class. 

Original Title: Durable reduction of mitral regurgitation after 2 years: another ace up the TMVR sleeve.

Reference: Georg Goliasch et al. JACC Cardiovasc Interv. 2021 May 7;S1936-8798(21)00822-0. Online ahead of print. doi: 10.1016/j.jcin.2021.04.047. Presentado simultáneamente en el EuroPCR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...